Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01429441 · ClinicalTrials.gov registry record · Phase 3
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
A Phase 3 study, sponsored by ThromboGenics.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT01429441 is a Phase 3 study that has completed, run by ThromboGenics. The registered enrollment target is 220 participants.
The verdict
NCT01429441, a Phase 3 study, has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
Interventions
- OTHER Sham injection
- DRUG Ocriplasmin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01429441
The ClinicalTrials.gov registry entry for NCT01429441 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham injection is the first listed.
NCT01429441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01429441 about?
NCT01429441 is a clinical study titled "Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole". The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
What is the current status of trial NCT01429441?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2011-10. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01429441?
The interventions under investigation include: Sham injection (OTHER), Ocriplasmin (DRUG).
Who is sponsoring clinical trial NCT01429441?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.